Thromboembolism

A large study of mortality in Cushing’s syndrome calculated a threefold higher mortality rate for these patients, with cerebrovascular and atherosclerotic vascular diseases and infection accounting for 50% of deaths, researchers reported.

Patients with anaplastic lymphoma kinase-mutant non-small cell lung cancer exhibited considerably higher risk for thromboembolism than those with EGFR-mutant or wild-type disease, study results showed.

Results presented at the Virtual EFORT Congress showed an association between the CHA2DS2-VASc score with risk of stroke, thromboembolism and death among patients with or without atrial fibrillation undergoing treatment for hip fracture.

Trauma patients who underwent emergency general surgery appeared to have a twofold higher risk for venous thromboembolism than patients who underwent elective surgery, according to study results published in JAMA Surgery.

Among a large cohort of transgender adults prescribed gender-affirming hormones, higher levels of cross-sex hormones did not increase the odds of hypertension, and hypertension diagnoses were fewer among transgender women who were ever prescribed progestins, according to data published in Transgender Health.

In patients who underwent surgical bioprosthetic valve implantation or repair, early postoperative anticoagulation with edoxaban was noninferior to warfarin for preventing thromboembolism and major bleeding during the first 3 months after the procedure, according to results of the ENAVLE trial presented at the virtual American College of Cardiology Scientific Session.

In patients with atrial fibrillation who had ACS or PCI, among those with prior stroke, transient ischemic attack or thromboembolism, those assigned a dual antithrombotic strategy of apixaban and a P2Y12 inhibitor had better outcomes than those assigned a vitamin K antagonist-based regimen, according to new data from the AUGUSTUS trial.

Among patients with atrial fibrillation on long-term dialysis, oral anticoagulants were not associated with decreased risk for thromboembolism and some of them elevated risk for bleeding, according to a meta-analysis.

The FDA approved rivaroxaban for the prevention of venous thromboembolism among acutely ill hospitalized patients who are at risk for blood clots but not at high risk for bleeding, according to a press release from the agent’s manufacturer.

Direct oral anticoagulants should be used to prevent venous thromboembolism among certain patients with cancer, as well as to treat those who develop blood clots, according to updated ASCO recommendations published in Journal of Clinical Oncology.